Beesetti Hemalatha, Khanna Navin, Swaminathan Sathyamangalam
a Department of Biological Sciences , Birla Institute of Technology and Science Pilani , Hyderabad , India.
b Recombinant Gene Products Group , International Centre for Genetic Engineering and Biotechnology , New Delhi , India.
Expert Opin Investig Drugs. 2016 Sep;25(9):1059-69. doi: 10.1080/13543784.2016.1201063. Epub 2016 Jun 24.
Dengue has emerged as the most significant arboviral disease of the current century. A drug for dengue is an urgent unmet need. As conventional drug discovery efforts have not produced any promising clinical candidates, there is a shift toward re-positioning pre-existing drugs for dengue to fast-track dengue drug development.
This article provides an update on the current status of recently completed and ongoing dengue drug trials. All dengue drug trials described in this article were identified from a list of >230 trials that were returned upon searching the World Health Organization's International Clinical Trials Registry Platform web portal using the search term 'dengue' on December 31(st), 2015.
None of the handful of drugs tested so far has yielded encouraging results. Early trial experience has served to emphasize the challenge of drug testing in the short therapeutic time window available, the need for tools to predict 'high-risk' patients early on and the limitations of the existing pre-clinical model systems. Significant investment of efforts and resources is a must before the availability of a safe, effective and inexpensive dengue drug becomes a reality. Currently, supportive fluid therapy remains the only option available for dengue treatment.
登革热已成为本世纪最重要的虫媒病毒病。治疗登革热的药物是迫切未得到满足的需求。由于传统的药物研发努力尚未产生任何有前景的临床候选药物，因此正转向重新定位现有药物用于登革热治疗，以加快登革热药物开发。
本文提供了近期完成和正在进行的登革热药物试验现状的最新信息。本文所述的所有登革热药物试验均从2015年12月31日在世界卫生组织国际临床试验注册平台门户网站上使用搜索词“登革热”进行搜索后返回的>230项试验列表中识别出来。
到目前为止，所测试的少数几种药物均未产生令人鼓舞的结果。早期试验经验凸显了在可用的短治疗时间窗内进行药物测试的挑战、尽早预测“高危”患者的工具的必要性以及现有临床前模型系统的局限性。在安全、有效且廉价的登革热药物成为现实之前，必须投入大量的努力和资源。目前，支持性液体疗法仍然是登革热治疗的唯一可用选择。
